Saxagliptin Global Buyers List: A B2B Sourcing and Market Intelligence Guide

Saxagliptin remains a cornerstone of type 2 diabetes management as a dipeptidyl peptidase-4 (DPP-4) inhibitor, marketed under brand names such as Onglyza and Kombiglyze XR. For API manufacturers, exporters, and procurement teams, identifying genuine buyers and understanding trade flows is essential for building reliable supply chains. This guide maps the global Saxagliptin buyer landscape using verified customs and trade data, regional demand insights, and practical sourcing intelligence.

Understanding the Saxagliptin Trade Landscape

Saxagliptin trade operates across two primary channels: bulk API (active pharmaceutical ingredient) and finished-dose formulations (tablets, fixed-dose combinations). The global market is shaped by patent expirations, regulatory approvals, and the growing demand for affordable diabetes therapies in emerging markets.

According to customs data, Saxagliptin trade spans 29 importing countries with 67 identified buyers and 65 suppliers recorded across global shipment databases. India has emerged as a dominant export hub, with Saxagliptin exports valued at $433.2 million across 331 shipments, classified under seven distinct HS codes.

The dominant HS code is 30049099 (other medicaments put up in measured doses for retail sale), accounting for 96.9% of all Saxagliptin trade at $419.7 million. This concentration under a single HS code simplifies customs classification for exporters and importers alike.

Top Saxagliptin Buyers and Importers

The buyer landscape is notably concentrated, with the top five buyers controlling 97.6% of total import value in key sourcing corridors. This concentration means that a small number of large pharmaceutical companies drive the majority of API and formulation demand.

Leading Importers from India

India serves as a major Saxagliptin sourcing origin, with 41 active buyers importing $4.0 million across 258 shipments. The top buyers ranked by import value include:

Rank	Buyer	Country	Import Value	Market Share
1	MYLAN PHARMACEUTICALS INC	United States	$2.5M	62.8%
2	MYLAN PHARMACEUTICALS INC (entity 2)	United States	$1.1M	26.5%
3	ALSHIFA PHARMA SCIENTIFIC DRUG	Iraq	$259.3K	6.4%
4	GLENMARK PHARMACEUTICALS INC	United States	$45.2K	1.1%
5	MYLAN PHARMACEUTICALS INC (entity 3)	United States	$25.7K	0.6%

Data source: Indian Customs (DGFT) shipping bill records

Mylan’s multiple importing entities demonstrate the company’s significant role in generic Saxagliptin distribution, particularly for the U.S. market. Alshifa Pharma Scientific Drug represents a key Middle Eastern buyer, sourcing finished-dose Saxagliptin for the Iraqi market.

Additional Verified Buyers

Beyond the top-ranked importers, additional verified Saxagliptin buyers include REGENCY PHARMA LIMITED (Mauritius), ASTRAZENECA PHARMA INDIA LTD (India), BPOST INTERNATIONAL EMC (Belgium), LAWRENCE WATERS (United States), SAVA HEALTHCARE LIMITED, and AUROVITAS PHARMA TAIZHOU CO LTD. These buyers represent a mix of generic pharmaceutical manufacturers, specialty distributors, and healthcare supply chain intermediaries.

For Mauritius specifically, key buyers of Indian Saxagliptin include REGENCY PHARMA LIMITED, REGENCY PHARMA LTD, and ZAPATERO INTERNATIONAL LIMITED, among others.

Regional Saxagliptin Demand Hubs

United States and North America

The United States is the largest single buyer market for Saxagliptin finished doses, driven by Mylan’s generic Onglyza distribution and Glenmark’s formulation imports. Saxagliptin 2.5 mg is approved in 75 countries, while the 5 mg strength is approved in 83 countries, including the European Union. The U.S. FDA initially approved Onglyza in July 2009, and subsequent fixed-dose combinations with metformin expanded the market further.

Europe

European Saxagliptin demand is characterized by API sourcing for generic manufacturing and finished-dose imports. Key European buyers identified in trade data include LEK PHARMACEUTICALS D D (Slovenia) and LEK D D (Ireland). Switzerland recorded 49 Saxagliptin import shipments from a small number of buyers, indicating concentrated but consistent demand. The EMA approved Saxagliptin in September 2009, and the saxagliptin/metformin fixed-dose combination is approved in 98 countries for type 2 diabetes treatment.

Middle East and Africa

The Middle East represents a growing Saxagliptin market, with Iraq emerging as a significant buyer through ALSHIFA PHARMA SCIENTIFIC DRUG. The DPP-4 inhibitor market in the Middle East and Africa is projected for steady growth, driven by rising diabetes prevalence and government healthcare initiatives. Key markets include Saudi Arabia, UAE, Kuwait, and Qatar, with hospital pharmacies and institutional buyers forming the primary procurement channels.

Asia-Pacific

China, India, and Southeast Asia constitute a complex Saxagliptin trade ecosystem. China hosts 5 API manufacturers with active regulatory filings, and the median Saxagliptin API export price stands at **$13,667 per kg**, with a range of $8,992 to $15,640. India serves as both a major exporter and importer of Saxagliptin, with 176 import shipments recorded, primarily for domestic formulation manufacturing and re-export.

Saxagliptin API Manufacturers and Supply Base

Understanding the supply side is critical for buyers evaluating Saxagliptin sourcing options. The global API landscape includes 18 manufacturers with active filings, of which 15 hold a US DMF or CEP. Leading API suppliers include:

• AstraZeneca (innovator, in-house production in UK, USA, Japan)
• Viatris, Fresenius Kabi, Suzhou Elly Chemicals (contract manufacturing, FDA/EMA/PMDA approved)
• Hetero Labs, Macleods Pharmaceuticals, Sun Pharma (India-based generic API suppliers)
• CTX Lifesciences (India-based, exports to 87+ countries, GMP and DMF support)

Sources: DrugPatentWatch, CTX Lifesciences, PharmaDB

Quality and regulatory compliance are non-negotiable for Saxagliptin API sourcing. Suppliers must meet >99% purity standards, comply with ICH Q7 guidelines, and hold valid approvals from agencies such as the FDA, EMA, or PMDA.

How to Find and Qualify Saxagliptin Buyers

Trade Data Platforms

The most reliable method for building a Saxagliptin buyers list is through customs trade data platforms. Services like Volza, TransDataNexus, and Export Genius provide verified shipment records that reveal actual buyer names, shipment frequencies, import values, and sourcing origins. These platforms allow suppliers to filter buyers by country, import volume, and product type (API vs. finished dose).

For example, Volza’s Saxagliptin directory identifies 54 active importers buying from 34 Indian suppliers, enabling targeted outreach. TransDataNexus provides ranked buyer profiles with contact information and shipment histories.

B2B Pharmaceutical Marketplaces

Platforms such as CPhI Online, PharmaOffer, and ChemicalBook list Saxagliptin API buyers and suppliers actively seeking trade partnerships. These platforms are particularly useful for smaller-volume API transactions and for identifying buyers in China and Southeast Asia.

Trade Shows and Industry Events

Pharmaceutical trade exhibitions—including CPhI Worldwide, CPHI India, and Pharmaconex—provide direct access to Saxagliptin buyers, distributors, and procurement managers. These events are ideal for establishing initial contact and qualifying buyer requirements for regulatory documentation and packaging specifications.

Procurement and Qualification Checklist

When engaging Saxagliptin buyers, suppliers should prepare the following:

1. Regulatory documentation: Certificate of Analysis (COA), Drug Master File (DMF) status, GMP certificates, and Free Sale Certificate where applicable.
2. Stability data: Supporting data for the destination market’s climatic zone.
3. Packaging flexibility: Ability to accommodate country-specific labeling and retail packaging requirements.
4. Minimum order quantity (MOQ) structuring: Tiered MOQs for trial lots, standard wholesale orders, and institutional volumes.
5. Incoterms and lead time clarity: Defined shipping terms and reliable delivery schedules to prevent supply disruptions.

AUROBINDO PHARMA LTD
CÔNG TY TNHH ASTRAZENECA VIỆT NAM
AUROLOGISTICS LLC
ASTRAZENECA PHARMA INDIA LIMITED
KAUSTUBHA SCIENTIFIC RESEARCH LABORATORYPRIVATE LI
SUSHEN MEDICAMENTOS PRIVATE LIMITED
CÔNG TY TNHH SẢN XUẤT NAVIS VIỆT NAM
UNITED STATES PHARMACOPEIA INDIA PRIVATE LIMITED
WORLDWIDE HEALTHCARE LIMITED
CHROMACHEMIE LABORATORY PRIVATE LIMITED
GLOBELINE INTERNATIONAL SHIPPING IN
ASTRAZENECA SA DE CV
ANALYTICA CHEMIE INC
CÔNG TY TNHH DỊCH VỤ THƯƠNG MẠI PHẠM NGUYỄN
CÔNG TY TNHH MTV NOVALAB
DISTRIBUIDORA FARMANOVA SOCIEDAD ANONIMA
MYLAN PHARMACEUTICALS INC
GLENMARK PHARMACEUTICALS INC
AUROLOGISTIC LLC
CÔNG TY CỔ PHẦN DƯỢC APIMED
ASTRAZENEZA S A
YUSEN LOGISTICS AMERICAS INC
CÔNG TY CỔ PHẦN KHOA HỌC CÔNG NGHỆ T T
FARMACIAS EOS SOCIEDAD ANONIMA
PT ASTRAZENECA INDONESIA
UNISON PHARMACEUTICALS PRIVATE LIMITED
CHROMO LABORATORIES INDIA PRIVATE LIMITED
CÔNG TY TNHH VẬT TƯ KHOA HỌC CÔNG NGHỆ T T
TIGAKA DISTRINDO PERKASA
TOKYO CHEMICAL INDUSTRY INDIA PRIVATE LIMITED
CHI NHÁNH CÔNG TY TNHH GLANDCORE
CTX LIFESCIENCES PRIVATE LIMITED
CÔNG TY CỔ PHẦN DƯỢC PHẨM SOHA VIMEX
CÔNG TY CỔ PHẦN DƯỢC PHẨM TIPHARCO
CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG I PHARBACO
CÔNG TY CỔ PHẦN DƯỢC PHẨM TV PHARM
CÔNG TY TNHH MỘT THÀNH VIÊN DƯỢC PHẨM 150 COPHAVINA
CÔNG TY TNHH SMART INGREDIENTS
CÔNG TY TNHH THƯƠNG MẠI H B C
DR REDDY LABORATORIES LIMITED
GLENMARK GENERICS INC
GLENMARK PHARMACEUTICALS INC USA
GLOBELINE INTERNATIONAL SHIPPING
GLOBELINE INTERNATIONAL SHIPPING INC
METROCHEM API PRIVATE LIMITED
NUTRABIOTICS PHARMACEUTICALS
SUCOPEIA REFERENCESTANDARDS OPC PRIVATE LIMITED
WORLDWIDE HEALTHCARE LTD
AUROLOGISTICS LLC 203 A WINDSOR
BIOCKRODT PHARMA
CHEMINOVA TECH
CÔNG TY CỔ PHẦN DƯỢC TRANG THIẾT BỊ Y TẾ BÌNH ĐỊNH BIDIPHAR
CÔNG TY CỔ PHẦN DƯỢC VẬT TƯ Y TẾ HẢI DƯƠNG
CÔNG TY CỔ PHẦN HÓA DƯỢC PHẨM MEKOPHAR
CÔNG TY CỔ PHẦN THƯƠNG MẠI VIỆT UY
CÔNG TY CỔ PHẦN US PHARMA USA
D H L KEELS PVT LTD
DR REDDY S LABORATORIES LTD
ELCON DRUGS AND FORMULATIONS LIMITED
M S MEDISURE LABORATORIES PAKISTAN PVT LTD
MYLAN LABORATORIES LIMITED
PHARMAFFILIATES ANALYTICS AND SYNTHETICS PRIVATE L
PHARMAFFILIATES PRIVATE LIMITED
SGATS LOGISTICS PVT LTD
SIMSON PHARMA LIMITED
THE IBN SINA PHARMACEUTICAL
TOPCLASS ENTERPRISES LLP
ULTRA INTERNATIONAL
WEATHER FOLDS PHARMACEUTICALS
ООО PHARM SECTOR
ООО ОЗОН

Conclusion

The global Saxagliptin buyers list is dominated by a concentrated group of large pharmaceutical importers, with Mylan, Glenmark, and Alshifa Pharma leading finished-dose procurement. India’s role as a Saxagliptin export powerhouse—with $433.2 million in trade value—makes it the primary sourcing origin for buyers worldwide. For API suppliers, the key to winning Saxagliptin contracts lies in regulatory compliance, competitive pricing, and the ability to serve both regulated and semi-regulated markets. By leveraging customs trade data, B2B platforms, and industry events, suppliers can build a qualified buyer pipeline and establish long-term partnerships in the growing diabetes therapeutics market.